Last updated: 2026-09-06 15:17:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Bicara Therapeutics Inc. (BCAX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $23,16, with a market capitalization of $1,56B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10,30 to $30,99. This page covers its latest market performance, valuation, price trends and company information.
$1,56B | |
$23,09 | |
$30,99 | |
$7,80 | |
$23,34 | |
253,16K | |
-- | |
-- | |
$30,99 | |
$10,30 | |
-- | |
-- |
Bicara Therapeutics Inc. (BCAX) last closed at $23,34 as of 2026-09-04 23:31:00, unchanged from the previous close of $23,34.
During the latest regular trading session, BCAX traded between $7,80 and $30,99, with a volume of 253,16K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, Bicara Therapeutics Inc. (BCAX) moved from $23,35 to $23,16, representing a decline of 0,81% ($0,19).
The stock traded between $22,96 and $26,73 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 426,71 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 62,2%
BCAX is currently trading at $23,16, placing it 62,2% of the way from its 52-week low of $10,30 to its 52-week high of $30,99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 103 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Bicara Therapeutics Inc. (BCAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.